Pulmonary vascular dysfunction in endstage cystic fibrosis: Role of NF-κB and endothelin-1

European Respiratory Journal

Volumn 34, Issue 6, 2009, Pages 1329-1337

  Henno, P ^a   Maurey, C ^a   Danel, C ^a,b   Bonnette, P ^d   Souilamas, R ^a,b   Stern, M ^d   Delclaux, C ^a,b   Levy M ^a,b,c   Israel Biet D ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

^d FOCH HOSPITAL   (France)

Author keywords

Endothelin 1; Genistein; Nuclear factor b; Obstructive lung disease

Indexed keywords

ACETYLCHOLINE; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); ENDOTHELIN 1; GENISTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; LUNG FIBROSIS; LUNG TRANSPLANTATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; PULMONARY VASCULAR DISEASE; VASCULAR RING; WESTERN BLOTTING;

ACETYLCHOLINE; ADULT; CYSTIC FIBROSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE EXPRESSION REGULATION; GENISTEIN; HOMEOSTASIS; HUMANS; HYPERTENSION, PULMONARY; MALE; NF-KAPPA B; VASCULAR DISEASES;

EID: 73249126089     PISSN: 09031936     EISSN: 13993003     Source Type: Journal    
DOI: 10.1183/09031936.00186908     Document Type: Article

References (41)

1. Mal H. Prevalence and diagnosis of severe pulmonary hypertension in patients with chronic obstructive pulmonary disease. Curr Opin Pulm Med 2007; 13: 114-119.
2. Wright JL, Levy RD, Churg A. Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment. Thorax 2005; 60: 605-609.
3. Dewachter L, Adnot S, Fadel E, et al. Angiopoietin/Tie2 pathway influences smooth muscle hyperplasia in idiopathic pulmonary hypertension. Am J Respir Crit Care Med 2006; 174: 1025-1033.
4. Perros F, Dorfmuller P, Souza R, et al. Fractalkine-induced smooth muscle cell proliferation in pulmonary hypertension. Eur Respir J 2007; 29: 937-943.
5. Sztrymf B, Yaici A, Girerd B, et al. Genes and pulmonary arterial hypertension. Respiration 2007; 74: 123-132.
6. Florea VG, Florea ND, Sharma R, et al. Right ventricular dysfunction in adult severe cystic fibrosis. Chest 2000; 118: 1063-1068.
7. Fraser KL, Tullis DE, Sasson Z, et al. Pulmonary hypertension and cardiac function in adult cystic fibrosis: role of hypoxemia. Chest 1999; 115: 1321-1328.
8. Roy R, Couriel JM. Secondary pulmonary hypertension. Paediatr Respir Rev 2006; 7: 36-44.
9. Vizza CD, Lynch JP, Ochoa LL, et al. Right and left ventricular dysfunction in patients with severe pulmonary disease. Chest 1998; 113: 576-583.
10. Belkin RA, Henig NR, Singer LG, et al. Risk factors for death of patients with cystic fibrosis awaiting lung transplantation. Am J Respir Crit Care Med 2006; 173: 659-666.
11. Fauroux B, Hart N, Belfar S, et al. Burkholderia cepacia is associated with pulmonary hypertension and increased mortality among cystic fibrosis patients. J Clin Microbiol 2004; 42: 5537-5541.
12. Venuta F, Rendina EA, De Giacomo T, et al. Timing and priorities for cystic fibrosis patients candidates to lung transplantation. Eur J Pediatr Surg 1998; 8: 274-277.
13. Montgomery GS, Sagel SD, Taylor AL, et al. Effects of sildenafil on pulmonary hypertension and exercise tolerance in severe cystic fibrosis-related lung disease. Pediatr Pulmonol 2006; 41: 383-385.
14. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980; 288: 373-376.
15. Dinh Xuan AT, Higenbottam TW, Pepke-Zaba J, et al. Reduced endothelium-dependent relaxation of cystic fibrosis pulmonary arteries. Eur J Pharmacol 1989; 163: 401-403.
16. McGrath LT, McCall D, Hanratty CG, et al. Individuals with cystic fibrosis do not display impaired endothelial function or evidence of oxidative damage in endothelial cells exposed to serum. Clin Sci (Lond) 2001; 101: 507-513.
17. Romano M, Collura M, Lapichino L, et al. Endothelial perturbation in cystic fibrosis. Thromb Haemost 2001; 86: 1363-1367.
18. Siahanidou T, Nicolaidou P, Doudounakis S, et al. Plasma immunoreactive endothelin levels in children with cystic fibrosis. Acta Paediatr 2000; 89: 915-920.
19. Chalmers GW, Macleod KJ, Sriram S, et al. Sputum endothelin-1 is increased in cystic fibrosis and chronic obstructive pulmonary disease. Eur Respir J 1999; 13: 1288-1292.
20. Humbert M. Update in pulmonary arterial hypertension 2007. Am J Respir Crit Care Med 2008; 177: 574-579.
21. Humbert M, Morrell NW, Archer SL, et al. Cellular and molecular pathobiology of pulmonary arterial hypertension. J Am Coll Cardiol 2004;43, 12: Suppl. S, 13S-24S.
22. Perros F, Dorfmuller P, Humbert M. Current insights on the pathogenesis of pulmonary arterial hypertension. Semin Respir Crit Care Med 2005; 26: 355-364.
23. Zhao XS, Pan W, Bekeredjian R, et al. Endogenous endothelin-1 is required for cardiomyocyte survival in vivo. Circulation 2006; 114: 830-837.
24. Robert R, Thoreau V, Norez C, et al. Regulation of the cystic fibrosis transmembrane conductance regulator channel by betaadrenergic agonists and vasoactive intestinal peptide in rat smooth muscle cells and its role in vasorelaxation. J Biol Chem 2004; 279: 21160-21168.
25. Drexler H, Hornig B. Endothelial dysfunction in human disease. J Mol Cell Cardiol 1999; 31: 51-60.
26. Knorre A, Wagner M, Schaefer HE, et al. DeltaF508-CFTR causes constitutive NF-kappaB activation through an ER-overload response in cystic fibrosis lungs. Biol Chem 2002; 383: 271-282.
27. Verhaeghe C, Remouchamps C, Hennuy B, et al. Role of IKK and ERK pathways in intrinsic inflammation of cystic fibrosis airways. Biochem Pharmacol 2007; 73: 1982-1994.
28. WeberAJ, Soong G, Bryan R, et al. Activation ofNF-kappaB in airway epithelial cells is dependent on CFTR trafficking and Cl- channel function. Am J Physiol Lung Cell Mol Physiol 2001; 281: L71-L78.
29. Perez A, Issler AC, Cotton CU, et al. CFTR inhibition mimics the cystic fibrosis inflammatory profile. Am J Physiol Lung Cell Mol Physiol 2007; 292: L383-L395.
30. Tabary O, Escotte S, Couetil JP, et al. High susceptibility for cystic fibrosis human airway gland cells to produce IL-8 through the I kappa B kinase alpha pathway in response to extracellular NaCl content. J Immunol 2000; 164: 3377-3384.
31. Tabary O, Zahm JM, Hinnrasky J, et al. Selective up-regulation of chemokine IL-8 expression in cystic fibrosis bronchial gland cells in vivo and in vitro. Am J Pathol 1998; 153: 921-930.
32. Uzun O, Demiryurek AT. Nuclear factor-kappaB inhibitors abolish hypoxic vasoconstriction in sheep-isolated pulmonary arteries. Eur J Pharmacol 2003; 458: 171-174.
33. Provencher S, Sitbon O, Humbert M, et al. Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension. Eur Heart J 2006; 27: 589-595.
34. Rosenzweig EB, Ivy DD, Widlitz A, et al. Effects of long-term bosentan in children with pulmonary arterial hypertension. J Am Coll Cardiol 2005; 46: 697-704.
35. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006; 47: 2049-2056.
36. Moran O, Zegarra-Moran O. A quantitative description of the activation and inhibition of CFTR by potentiators: Genistein. FEBS Lett 2005; 579: 3979-3983.
37. Michoud MC, Robert R, Hassan M, et al. Role of the CFTR channel in human airway smooth muscle. Am J Respir Cell Mol Biol 2009; 40: 217-222.
38. Robert R, Norez C, Becq F. Disruption of CFTR chloride channel alters mechanical properties and cAMP-dependent Cltransport of mouse aortic smooth muscle cells. J Physiol 2005; 568: 483-495.
39. Robert R, Savineau JP, Norez C, et al. Expression and function of cystic fibrosis transmembrane conductance regulator in rat intrapulmonary arteries. Eur Respir J 2007; 30: 857-864.
40. Hamalainen M, Nieminen R, Vuorela P, et al. Anti-inflammatory effects of flavonoids: genistein, kaempferol, quercetin, and daidzein inhibit STAT-1 and NF-kappaB activations, whereas flavone, isorhamnetin, naringenin, and pelargonidin inhibit only NF-kappaB activation along with their inhibitory effect on iNOS expression and NO production in activated macrophages. Mediators Inflamm 2007; 2007: 45673.
41. Tabary O, Escotte S, Couetil JP, et al. Genistein inhibits constitutive and inducible NFkappaB activation and decreases IL-8 production by human cystic fibrosis bronchial gland cells. Am J Pathol 1999; 155: 473-481.